End-to-end drug development workflow

The topic of end to end drug development workflow will be explored through the stages of end to end drug development, from early discovery through pre clinical and clinical testing, regulatory submission, and post marketing surveillance. We will examine how candidate drugs are identified, optimized, and tested for safety and efficacy, as well as the major hurdles and regulatory requirements at each stage. The lecture will also discuss the importance of multi disciplinary collaboration, strategic risk management, and emerging innovations such as precision medicine and artificial intelligence in this complex process. We will explore how a potential medicine moves from a lab concept to routine clinical use. Drug development is lengthy, costly and high risk, often taking over a decade with high attrition at each stage. Each new medicine starts as a research idea for an unmet need, but few reach the market, requiring coordinated scientific, regulatory and commercial efforts. An understanding of this pathway is vital for life sciences professionals. The earliest phase, drug discovery identifies promising biological targets, often proteins or genes linked to disease. Researchers use approaches like target based and phenotypic screening, as well as AI driven methods to nominate and optimize candidate molecules. Lead molecules are iteratively refined to improve efficacy and drug like properties. Pre clinical studies then focus on safety and pharmacokinetics,